Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent prior to initiation of any study procedures~* History of an influenza-like illness defined as:~  1) One or more respiratory symptom (cough, sore throat, or nasal symptoms)~* Onset of illness no more than 48 hours before screening, defined as when the participant experienced at least one respiratory symptom~* Willing to have samples stored~* Positive test for influenza (either rapid antigen or polymerase chain reaction \[PCR\]); randomization could proceed in cases of discrepant results (one positive and one negative)~Exclusion Criteria:~* Hospitalization at the time of screening~* Presence of a medical condition(s) that had been associated with increased risk of complications from influenza~  1. Aged 65 years of age or older~ 2. Asthma~ 3. Neurological and neuro-developmental conditions (including disorders of the brain, spinal cord, peripheral nerve, and muscle, such as cerebral palsy, epilepsy \[seizure disorders\], stroke, moderate to severe developmental delay, muscular dystrophy, or spinal cord injury)~ 4. Chronic lung disease (such as chronic obstructive pulmonary disease \[COPD\] or cystic fibrosis)~ 5. Heart disease (such as congenital heart disease, congestive heart failure, or coronary artery disease)~ 6. Blood disorders~ 7. Endocrine disorders (such as diabetes mellitus)~ 8. Kidney disorders~ 9. Liver disorders~ 10. Metabolic disorders (such as inherited metabolic disorders or mitochondrial disorders)~ 11. Weakened immune system due to disease or medication (such as people with HIV/AIDS or cancer, or use of chronic steroids or other medications causing immune suppression)~ 12. Pregnant or 4 weeks postpartum~ 13. Body mass index (BMI) greater than or equal to 40~* Breastfeeding~* Inability to take oral medication or a history of gastrointestinal malabsorption that would preclude the use of oral medication~* Received more than one dose of any antiviral influenza medication since onset of influenza symptoms~* Known end stage kidney dysfunction (e.g., creatinine clearance less than 30 mL/min)~* Known hypersensitivity to oseltamivir, peramivir, or zanamivir~* Received live attenuated influenza virus vaccine within 3 weeks prior to study entry~* Use of any investigational drug within 30 days or 5 half-lives (whichever was longer) prior to study entry~* Participated in other research protocols that required more than 100mL of blood to be drawn in a 4-week period that overlapped with this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Oseltamivir (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).